Last reviewed · How we verify

Eastern Health, Canada — Portfolio Competitive Intelligence Brief

Eastern Health, Canada pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
18F-2-fluoro-2-deoxy-D-glucose 18F-2-fluoro-2-deoxy-D-glucose phase 3 Positron emission tomography (PET) imaging agent Glucose transporter (GLUT1) and hexokinase Oncology, Neurology, Cardiology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre hospitalier de l'Université de Montréal (CHUM) · 1 shared drug class
  2. National Heart, Lung, and Blood Institute (NHLBI) · 1 shared drug class
  3. Ochsner Health System · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Eastern Health, Canada:

Cite this brief

Drug Landscape (2026). Eastern Health, Canada — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eastern-health-canada. Accessed 2026-05-16.

Related